Literature DB >> 11350732

Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor.

I Zachary1.   

Abstract

Vascular endothelial growth factor (VEGF) is essential for angiogenesis in health and pathophysiology, and it is currently a major focus for drug targeting in the development of treatments for diverse human diseases. Recently, we proposed that VEGF could also play a role as a vascular protective factor in the adult vasculature and in disease. In this model, vascular protection is defined as a VEGF-induced enhancement of endothelial functions that mediate the inhibition of vascular smooth muscle cell proliferation, enhanced endothelial cell survival, suppression of thrombosis, and anti-inflammatory effects. A feature of this model is that protective effects of VEGF are essentially independent of angiogenesis or endothelial cell proliferation. VEGF-dependent cell survival and VEGF-induced synthesis of nitric oxide and prostacyclin are likely to be key mediators of a vascular protective effect. Vascular protection should help to improve insight into the underlying mechanisms of cardiovascular actions of VEGF and prove valuable for developing novel therapeutic approaches to cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350732     DOI: 10.1152/ajpcell.2001.280.6.C1375

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  72 in total

1.  Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.

Authors:  Sarah J O'Meara; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

Review 2.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  Effect of cytokines secreted by human adipose stromal cells on endothelial cells.

Authors:  Bingong Li; Qiutang Zeng; Hongxiang Wang; Xiaobo Mao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

4.  Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology.

Authors:  Em Dietrich; K Antoniades
Journal:  Hippokratia       Date:  2012-07       Impact factor: 0.471

5.  Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril.

Authors:  G H Oliveira-Paula; R Lacchini; V Fontana; P S Silva; C Biagi; Jose E Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2015-05-24       Impact factor: 2.953

6.  Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.

Authors:  Ranjana H Advani; Fangxin Hong; Sandra J Horning; Brad S Kahl; Judith Manola; Lode J Swinnen; Thomas M Habermann; Kristen Ganjoo
Journal:  Leuk Lymphoma       Date:  2011-12-05

7.  Endothelium-Targeted Deletion of microRNA-15a/16-1 Promotes Poststroke Angiogenesis and Improves Long-Term Neurological Recovery.

Authors:  Ping Sun; Kai Zhang; Sulaiman H Hassan; Xuejing Zhang; Xuelian Tang; Hongjian Pu; R Anne Stetler; Jun Chen; Ke-Jie Yin
Journal:  Circ Res       Date:  2020-03-05       Impact factor: 17.367

8.  Circulating vascular growth factors and central hemodynamic load in the community.

Authors:  Justin P Zachariah; Vanessa Xanthakis; Martin G Larson; Joseph A Vita; Lisa M Sullivan; Holly M Smith; Radwan Safa; Xuyang Peng; Naomi Hamburg; Daniel Levy; Douglas B Sawyer; Gary F Mitchell; Ramachandran S Vasan
Journal:  Hypertension       Date:  2012-02-27       Impact factor: 10.190

9.  Transplantation of adult neural progenitor cells transfected with vascular endothelial growth factor rescues grafted cells in the rat brain.

Authors:  Martin H Maurer; Christine Thomas; Heinrich F Bürgers; Wolfgang Kuschinsky
Journal:  Int J Biol Sci       Date:  2007-12-03       Impact factor: 6.580

Review 10.  Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Authors:  Kristy J Gotink; Henk M W Verheul
Journal:  Angiogenesis       Date:  2009-12-11       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.